Try our Advanced Search for more refined results
Life Sciences
-
April 22, 2026
Judge Lets Pharma Co. Seal Parts Of Ex-GC's Retaliation Suit
A Texas state judge on Wednesday granted Houston-based Empower Clinic Services LLC's bid to permanently and partially seal a petition by its former general counsel that alleges a smear campaign by the company after he confronted them about conduct he said was unlawful.
-
April 22, 2026
Sorrento, M3 Get Pause On RICO Suit Naming Jackson Walker
A Texas bankruptcy judge on Wednesday agreed to put on hold a lawsuit in California federal court alleging Jackson Walker LLP and executives at Sorrento Therapeutics and M3 Partners conspired to forum shop in Texas so the drug developer could seek Chapter 11 protection there.
-
April 22, 2026
Oura Hit With New Patent Suit Over Fitness Wearables
Zepp Health has hit Oura Health with a lawsuit in the Eastern District of Texas accusing the Finnish company of infringing a series of patents on wearable fitness devices, the latest salvo in a wider patent fight between the companies.
-
April 22, 2026
Ex-Conn. Prosecutor Fights Drug Co. Bid To Appeal DQ Denial
Insurers Humana Inc. and Molina Healthcare Inc. urged a federal judge to turn down a group of generic-drug makers' request for an immediate trip to the Third Circuit, arguing the drugmakers' bid for a second chance to disqualify Connecticut's former assistant attorney general from an antitrust case was not qualified for an interlocutory appeal.
-
April 22, 2026
4 Firms Build Amneal's Up To $1.1B Kashiv Biosimilars Buy
Biopharmaceutical company Amneal Pharmaceuticals Inc. on Wednesday unveiled plans to acquire biosimilars-focused Kashiv BioSciences LLC in a deal worth up to $1.1 billion that was built by four law firms.
-
April 22, 2026
Chancery Sends Masimo Ex-CEO Pay Fight To California
The Delaware Chancery Court sided with former Masimo Corp. CEO Joe E. Kiani in his fight with the global medical technology company, dismissing the company's lawsuit over a disputed $450 million severance package and ruling that the case must proceed in California, not Delaware.
-
April 21, 2026
Armistice Capital Head Calls COVID Stock Rise 'Fun,' 'Lucky'
Armistice Capital's founder defended his hedge fund Tuesday from claims it pump-and-dumped $250 million in Vaxart stock during the COVID-19 pandemic, telling a California federal jury that he and his fund got "lucky" and that the stock's rapid surge was "fun."
-
April 21, 2026
Merck Beats Minn. Hockey Player's Talc Mesothelioma Claims
A Chicago jury has found Merck & Co. not liable for a hockey player's mesothelioma allegedly caused by the Dr. Scholl's talc foot powder he used regularly for years.
-
April 21, 2026
Biotech Co. Investors Clash Over 'Self-Dealing' Claim
Attorneys for a biopharmaceutical and technology company stockholder and a group of venture investors sharply disagreed Tuesday over whether a financing deal was a lifeline for a struggling company or a self-serving maneuver that enriched insiders, as they argued a motion to dismiss the derivative suit in the Delaware Chancery Court.
-
April 21, 2026
Congress Rallies More For Bills On Copyrights Than Patents
There have been more intellectual property bills floated in Congress that are supportive of copyright rights than patent rights, according to a new report looking at how lawmakers treat the IP system.
-
April 21, 2026
Amgen Faces ERISA Suit Over Health Plan Tobacco Surcharge
A former Amgen Inc. employee filed a proposed class action in California federal court Tuesday alleging the biotech company discriminatorily imposes an "egregiously high" $150-a-month surcharge on employees who use tobacco products, while failing to adequately notify them of reasonable pathways to avoid the fees, in violation of federal benefits law.
-
April 21, 2026
Pfizer, Dexcel Take 2 Patents Off Table For Bench Trial
Drugmaker Pfizer and an Israeli competitor that is seeking to create a generic version of a Pfizer heart medication said Tuesday they have reached an agreement to remove two asserted patents from a trial set to start next week.
-
April 21, 2026
Fed. Circ. Keeps Banner Witcoff And Saiber Off Patent Case
The Federal Circuit kept intact the disqualification of two law firms from a patent ownership fight on Tuesday, saying it had not been shown a district judge made a clear error in removing them.
-
April 21, 2026
Pot Management Co. Says It's Allowed Biz Tax Deduction
A California-based management company linked to cannabis operations is challenging the IRS over a $4.2 million tax bill, according to a U.S. Tax Court petition, arguing that the company does not traffic in controlled substances that would otherwise bar it from claiming business deductions.
-
April 21, 2026
Squires Stands By Ending Skincare IPR Over ITC Overlap
U.S. Patent and Trademark Office Director John Squires has shot down Sinclair Pharma Ltd.'s request to revive its challenge to Hydrafacial LLC's skin treatment patent, which the director had terminated based on related proceedings at the U.S. International Trade Commission.
-
April 21, 2026
Novo Nordisk Unit Can't Slip Former Exec's Sex, Age Bias Suit
A Novo Nordisk unit must face a former finance director's lawsuit claiming she was fired because she was an older woman who complained about a male co-worker's behavior, with a North Carolina federal judge ruling her allegations were detailed enough to stay in court.
-
April 21, 2026
Purdue Pharma Sentencing Punted For In-Person Attendance
A New Jersey federal judge delayed Oxycontin maker Purdue Pharma's criminal sentencing by a week, saying rescheduling would give an in-person attendance option to hundreds of observers who tuned in virtually Tuesday.
-
April 21, 2026
Ga. Justices Confront Fed, State Power Divide In Bio-Lab Suit
Georgia's highest court seemed to struggle Tuesday with whether it had the authority to tell a federal judge if residents suing chlorine products company Bio-Lab Inc. over the aftermath of a 2024 fire could ask for medical monitoring as part of their class action.
-
April 21, 2026
Philly Zantac Judge Again Declines To Recuse From Cases
A Philadelphia judge overseeing the Zantac mass tort litigation against GlaxoSmithKline has once again denied a motion to recuse himself from the cases, claiming that his wife's affiliation with a firm representing a defendant in the litigation did not present a conflict that required him to step away.
-
April 20, 2026
Armistice Head Testifies He Accidentally Deleted Texts
Armistice Capital's founder, who is facing investor claims that the hedge fund dumped its artificially inflated shares in pharmaceutical company Vaxart for $250 million, told a California federal jury Monday that during a physical therapy session held over Skype, he accidentally deleted key text messages with another Armistice executive.
-
April 20, 2026
Beasley Allen Pro Hac Vice Revoked In Philly J&J Talc Cases
A Pennsylvania state court has booted Beasley Allen Law Firm attorneys from representing consumers in nine cases that link Johnson & Johnson's talcum powder to ovarian cancer, saying their pro hac vice admission was inappropriate given the firm's dealings with an attorney who previously represented the company.
-
April 20, 2026
Quinn Emanuel May Face More Sanctions In Guardant Fight
Guardant Health Inc. urged a California federal judge on Monday to make Quinn Emanuel pay nearly $1.3 million on top of $3 million in sanctions already imposed over misrepresentations lawyers made representing its rival Natera Inc., prompting the judge to criticize Quinn Emanuel lawyers for making distinctions so fine they veer into misrepresentation.
-
April 20, 2026
Philip Morris Unfairly Gains From Label Ruling, 11th Circ. Told
Philip Morris cannot be the only company allowed to not follow a rule requiring cigarette makers to add graphic warnings to their labels, R.J. Reynolds and a coalition of tobacco businesses have told the Eleventh Circuit, suggesting that consumers might assume its cigarettes are safer than theirs.
-
April 20, 2026
ImmunityBio Stock Fell After FDA Letter, Derivative Suit Says
Biotechnology company ImmunityBio Inc.'s stock slipped by 21% after misleading statements on a podcast by the company's founder about its lead cancer drug prompted the issuance of a warning letter from the U.S. Food and Drug Administration, according to a shareholder derivative suit in California federal court.
-
April 20, 2026
SEC Says Adviser Traded On Firm Clients' Confidential Info
The U.S. Securities and Exchange Commission sued an ex-investment advisory firm associate in Manhattan federal court on Monday, accusing him of using a close relative's brokerage account to trade ahead of market-moving announcements by three biopharmaceutical and biotechnology companies that his firm was researching.
Editor's Picks
-
Supreme Court Will Tackle Patent Enablement In Amgen Case
The U.S. Supreme Court on Friday agreed to review Section 112 of the Patent Act for the second time in the law's history, accepting Amgen's request to consider how much a patent must disclose in order to meet enablement requirements.
-
A Circuit-By-Circuit Guide To FCA Suits After High Court Snub
The U.S. Supreme Court's refusal to resolve one of the False Claims Act's most consequential controversies leaves circuit courts deeply divided over whistleblower pleading obligations in ways that will reverberate nationwide, attorneys say. Here, Law360 explores each circuit's approach and scenarios that might finally trigger high court intervention.
-
Inside The Collapse Of A Pioneering Opioid Case For DOJ
The U.S. Department of Justice launched a "terribly flawed" criminal case against a drug distributor and several individuals amid pressure to alleviate Appalachia's opioid crisis, and a newly confirmed U.S. attorney displayed "courage and guts" by ending the case last month, defense counsel told Law360 in an expansive interview.
Expert Analysis
-
Fresenius Ruling May Shift Anti-Kickback Enforcement
The Ninth Circuit's recent decision in Fresenius v. Bonta suggests that businesses have a First Amendment right to donate to certain charities, even if those donations are motivated by economic self-interest, potentially calling into question years of Anti-Kickback Statute proceedings against pharmaceutical manufacturers for making similar donations, says Jonah Knobler at Patterson Belknap.
-
Written Consent Ruling May Signal Change For Telemarketing
The Fifth Circuit's ruling in Bradford v. Sovereign Pest Control is a takedown of the Federal Communications Commission's prior express written consent regulation, and because Loper Bright empowers courts to disregard agency interpretations, Telephone Consumer Protection Act litigants now have an opportunity to challenge previously settled FCC regulations, orders and interpretations, say attorneys at Manatt.
-
Series
Law School's Missed Lessons: How To Draft Pleadings
Most law school graduates step into their first jobs without ever having drafted a complaint, answer, motion or other type of pleading, but that gap can be closed by understanding the strategy embedded in every filing, writing with clarity and purpose, and seeking feedback at every step, says Eric Yakaitis at Haug Barron.
-
At The Fed. Circ., Means-Plus-Function Is Not Quite Dead
Recent Federal Circuit opinions confirm that means-plus-function claims continue to be drafted, issued, litigated and even infringed — but minding the restrictions imposed over the years by courts and statute requires three steps, says Jay Yates at Patterson & Sheridan.
-
E-Discovery Quarterly: Recent Rulings On ESI Control
Several recent federal court decisions have perpetuated a split over what constitutes “control” of electronically stored information — with judges divided on whether the standard should turn on a party's legal right or practical ability to obtain the information, say attorneys at Sidley.
-
Opinion
USPTO Should Let Inventors Valuate Patents In Prosecution
By building patent valuation into the application process, rather than waiting until potential litigation years down the line, the U.S. Patent and Trademark Office would streamline the process for inventors protecting and enforcing their patents, says John Powers at Powers IP.
-
2 Discovery Rulings Break With Heppner On AI Privilege Issue
While a New York federal court’s recent ruling in U.S. v. Heppner suggests that some litigants’ communications with AI tools are discoverable, two other recent federal court decisions demonstrate that such interactions generally qualify for work-product protection under the Federal Rules of Civil Procedure, says Joshua Dunn at Brown Rudnick.
-
Series
Isshin-Ryu Karate Makes Me A Better Lawyer
My involvement in martial arts, specifically Isshin-ryu, which has principles rooted in the eight codes of karate, has been one of the most foundational in the development of my personality, and particularly my approach to challenges — including in my practice of law, says Kaitlyn Stone at Barnes & Thornburg.
-
Microplastics On Water Contaminant List Could Spur Claims
The U.S. Environmental Protection Agency's proposal to include microplastics in its draft sixth Contaminant Candidate List under the Safe Drinking Water Act could influence consumer fraud claims and enforcement by state attorneys general, as well as claims against manufacturers from entities facing regulatory compliance costs, says Arie Feltman-Frank at Jenner & Block.
-
USPTO's AI Search Pilot May Reshape Patent Filing Strategy
The U.S. Patent and Trademark Office's new artificial intelligence search pilot aims to introduce earlier visibility into the prior art landscape, potentially influencing patent filing considerations and shifting the role of counsel to an earlier stage of the prosecution process, say attorneys at Foley & Lardner.
-
Peptide Policy Is Shifting Toward Sanctioned Compounding
The policy landscape for peptides is undergoing a significant shift under the Trump administration, moving toward a complex system of verified compounding and complementary enforcement that will likely bring peptides firmly back into the sphere of legitimate consumer products, say attorneys at Sheppard.
-
Keys To Building Defensible Psychedelic Therapy Programs
Given the rapidly evolving legal environment for psychedelic therapies and heightened liability and compliance risks facing providers, meticulous documentation, robust risk management protocols, and proactive engagement with professional organizations and insurers are essential strategies, say Kimberly Chew at Husch Blackwell and L. Alison McInnes at Mindful Health Solutions.
-
Opinion
State Bars Need To Get Specific About AI Confidentiality
Lawyers need to put actual client information into artificial intelligence tools to get their full value, but they cannot confidently do so until state bars offer clear, formal authority on which plan tiers of the three most popular generative AI tools are safe to use when sharing specific client details, says attorney Nick Berk.
-
Series
Alpine Skiing Makes Me A Better Lawyer
Skiing has shaped habits I rely on daily as an attorney — focus, resilience and the ability to remain steady when circumstances shift rapidly — and influences the way I approach legal strategy, client counseling and teamwork, says Isaku Begert at Marshall Gerstein.
-
FDA Guidance May Move Goalposts For Form 483 Responses
New draft guidance from the U.S. Food and Drug Administration provides formal insight on how drug manufacturers are expected to respond to Form 483s, raising some concerns about the agency's timelines and expectations, say attorneys at Cooley.